Binding Members for Human Cytomegalovirus

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes novel binding members, particularly fully human antibody molecules, that can specifically bind to unique epitopes on the gB protein of human cytomegalovirus (hCMV). Unlike prior antibodies, these bind to newly defined regions (AD-4 and AD-5) on gB, are highly potent at neutralizing a broad range of hCMV strains, and can be used in the treatment, prevention, and diagnosis of hCMV infections, especially in vulnerable populations such as newborns and immunocompromised individuals.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of hCMV infections, especially in immunocompromised patients such as organ transplant recipients or HIV-infected individuals.
• Prophylactic (preventive) administration to at-risk populations, including pregnant women to reduce congenital cytomegalovirus transmission, and newborns to prevent severe symptoms.
• Development of diagnostic assays for detecting hCMV infection or monitoring immune response via antibody detection.
• Production of pharmaceutical compositions (e.g., intravenous infusions or subcutaneous injections) for hospital or outpatient use.
• Use as part of a combination therapy with existing antiviral drugs to enhance efficacy and/or reduce antiviral resistance.
• Implementation in biosensor or lab-based systems for research or blood screening purposes.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific targeting of novel and conserved regions on hCMV gB protein, making resistance less likely and enabling broad neutralization across hCMV strains.
• High neutralization potency—effective at low concentrations, allowing for lower dosages and potentially fewer side effects or more convenient administration (e.g., subcutaneous injection).
• Fully human antibody structure minimizes risk of immune response or rejection, enhancing safety and suitability for repeat dosing.
• Effective across multiple cell types relevant to hCMV infection (fibroblasts, endothelial, epithelial, dendritic cells), ensuring comprehensive protection.
• Potential to replace or supplement existing therapies (e.g., IVIG, antiviral drugs), many of which have limitations (toxicity, risk to specific populations like children or pregnant women, resistance).
• Manufacturable via recombinant technology, allowing for scalable, consistent, pathogen-free production (unlike plasma-derived products).

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to binding members, especially antibody molecules, which neutralise the biological effects of human cytomegalovirus (hCMV). The binding members are useful for the treatment and prophylaxis of hCMV infection.